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Abstract
Peptidyl-prolyl isomerases catalyze the conversion between cis and trans isomers of proline. The cyclophilin family of
peptidyl-prolyl isomerases is well known for being the target of the immunosuppressive drug cyclosporin, used to combat
organ transplant rejection. There is great interest in both the substrate specificity of these enzymes and the design of
isoform-selective ligands for them. However, the dearth of available data for individual family members inhibits attempts to
design drug specificity; additionally, in order to define physiological functions for the cyclophilins, definitive isoform
characterization is required. In the current study, enzymatic activity was assayed for 15 of the 17 human cyclophilin
isomerase domains, and binding to the cyclosporin scaffold was tested. In order to rationalize the observed isoform
diversity, the high-resolution crystallographic structures of seven cyclophilin domains were determined. These models,
combined with seven previously solved cyclophilin isoforms, provide the basis for a family-wide structure:function analysis.
Detailed structural analysis of the human cyclophilin isomerase explains why cyclophilin activity against short peptides is
correlated with an ability to ligate cyclosporin and why certain isoforms are not competent for either activity. In addition, we
find that regions of the isomerase domain outside the proline-binding surface impart isoform specificity for both in vivo
substrates and drug design. We hypothesize that there is a well-defined molecular surface corresponding to the substrate-
binding S2 position that is a site of diversity in the cyclophilin family. Computational simulations of substrate binding in this
region support our observations. Our data indicate that unique isoform determinants exist that may be exploited for
development of selective ligands and suggest that the currently available small-molecule and peptide-based ligands for this
class of enzyme are insufficient for isoform specificity.
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Introduction
Cyclophilins are peptidyl-prolyl isomerases (PPIases: EC
5.2.1.8) and are characterized by their ability to catalyze the
interconversion of cis and trans isomers of proline [1]. Cyclophilins
and the structurally unrelated FK506 binding proteins were
initially described as the in vivo receptors for the natural products
cyclosporin, FK506/tacrolimus, and rapamycin/sirolimus [2,3].
The immunosuppressant effect of these natural products, while
revolutionizing the field of organ transplantation, were eventually
determined to be unrelated to the inherent isomerase activity of
the PPIases [4]. However, these small molecules bind to the active
site of PPIases with high affinity and are capable of blocking
isomerase activity against peptide substrates, making them a useful
tool for biochemical and cellular assays of PPIase function [5].
The physiological function of cyclophilin PPIase activity has
been for many years described as a chaperone or foldase [6,7].
Certainly this functionality is well documented, for instance in the
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Hsc70) [8] or in the interplay between NinaA and rhodopsin in
Drosophila [9]. In addition, the isomerase activity of at least two
cyclophilin isoforms is crucial for host:virus interactions and for
viral maturation processes, and this activity seems to be mediated
through the PPIase active site [10,11]. However, it has become
increasingly apparent that isomerization of proline is not the sole
function of the PPIases, with the first example being the
nonimmunophilin Pin1, a PPIase of the parvulin type. Pin1 is
able to catalyze isomerization of the proline bond for target
substrates only when a serine or threonine preceding the target
proline is phosphorylated [12]. This phosphorylation-dependent
isomerization places Pin1 directly in the context of traditional
signal transduction pathways, including those involved in cell
proliferation and tumorigenesis [13]. The identification of Pin1
substrates revitalized the search for additional functions of the
immunophilin-type PPIases; although there is no example of
phosphorylation-dependent isomerization for either FK506 bind-
ing proteins or for cyclophilins, a subset of substrates for these
types of PPIases are certainly also dependent on nonchaperone
functions. PPIA, along with classical functions in the chaperone-
mediated processes outlined above, interacts with the receptor
tyrosine kinase Itk post-translationally and modulates the activity
state of the already folded protein in vivo [14]. PPIA also is known
to modulate HIV infectivity by interacting with a proline-
containing sequence in the capsid protein Gag, also in the context
of a well-folded protein module [15]. More recently, PPIA has
been shown to interact with CD147 in a manner that is proline-
dependent and mediated through the active site of the isomerase,
but does not contribute to CD147 folding per se [16,17]. In
addition, both PPIA and the highly similar PPIB have been shown
to interact with NS5B, an RNA-dependent RNA polymerase
necessary for hepatitis C viral replication [10,18]. The three other
single-domain PPIases—which encode only the PPIase domain
and, in the case of PPIB and PPIC, a signal sequence—and the 13
multidomain PPIases are less well characterized; most of what is
known for these cyclophilins centers not on the isomerase active
site but on distinct regions with no known enzymatic function. For
instance, the single domain PPIase PPIH (SnuCyp20) participates
in the spliceosome through interactions with the 60K component
of the tri-snRNP, also known as hPRP4; however, the co-crystal
structure of PPIH with a peptide derived from hPRP4 showed that
this interaction was mediated exclusively through a face opposite
that of the active site [19]. A similar situation was found in another
spliceosomal cyclophilin, PPIL1, which interacts with the protein
SKIP; NMR data indicate that the chemical shift perturbations in
PPIL1 upon SKIP binding did not involve residues involved in
proline turnover, and that binding to SKIP occurred even when
PPIL1 was bound to cyclosporin A [20]. Finally, PPIE has an
RNA-recognition motif (RRM) and has been reported to have
RNA-specific isomerase activity [21].
Cyclophilins have been implicated in diverse signaling
pathways, including mitochondrial apoptosis [22,23], RNA
splicing [24,25], and adaptive immunity [26]. However, the
proteins that are substrates for cyclophilins in these pathways
have not been identified. Moreover, even basic questions
concerning the biochemical properties of these enzymes have
not been fully addressed. For instance, of the 17 annotated
human cyclophilins only seven have been tested for isomerase
activity or for the ability to bind cyclosporin [20,27–32]. In vitro
techniques aimed at delineating substrate specificity for the
canonical family member PPIA have been only moderately
successful; mutational analysis of short proline-containing motifs
has found that PPIA is a very broadly specific enzyme [33,34],
despite the relatively small number of in vivo–validated
substrates. In the case of phage display, the optimized binding
sequence does not correspond to the substrate determinants that
have been found in vivo for this isoform, and this sort of
randomized screening has not been accomplished for any of the
less ubiquitous isoforms [35]. Generally, the issue of in vitro
versus in vivo substrate selectivity for the isomerases is
problematic: for a given isomerase for which there is no
knowledge of in vitro substrate specificity, it is difficult to find
and validate in vivo substrates. Even for the isoforms that have
been tested in vitro for their substrate preferences, there has been
little or no correlation with later discovery of in vivo substrate
sequences. Clues in some cases may be derived from the identity
of other domains expressed in tandem with the cyclophilin
domain; for instance, the RRM domain previously mentioned
implies an RNA targeting function for PPIE and PPIL4, and
likewise the U-box motif of PPIL2 implies involvement in
ubiquitin conjugation pathways [36]. The WD-40 repeat of
PPWD1 most likely confers a protein:protein interaction function,
as this is its main function in other systems; the same holds true
for the TPR motifs of RanBP2 and PPID. However, useful
comparisons of in vitro activity with in vivo physiology must wait
until the cyclophilin family is more fully characterized with data
from either or both lines of research.
In this study, we have screened 15 of the 17 human cyclophilins
for their ability to catalyze proline isomerization against standard
tetrapeptide proline motifs. We also have determined binding
affinities for each cyclophilin family member for the natural
product cyclosporin, and have determined the structures of seven
PPIase domains to high resolution using X-ray crystallography.
These extensive studies reveal interesting biochemical and
enzymatic diversity that is consistent with structural data. The
structures also provide an opportunity to assess the cyclophilin
family for regions of diversity among all family members. In
addition, in silico methods based on a family-wide structural
analysis were used to characterize a molecular feature contiguous
with the canonical active site that may account for substrate
specificity. This new description of the cyclophilin peptidyl-prolyl
isomerase family highlights regions of diversity that may prove
crucial for future physiologically relevant substrate identification
and chemical probe development.
Author Summary
Cyclophilins are proteins that catalyze the isomerization of
prolines, interconverting this structurally important amino
acid between cis and trans isomers. Although there are 17
cyclophilins in the human genome, the function of most
cyclophilin isoforms is unknown. At least some members
of this protein family are of interest for clinically relevant
drug design, as they are targets of the drug cyclosporin,
which is used as an immunosuppressant to treat patients
following organ transplantation. The absence of a com-
prehensive picture of the similarities and differences
between the different members of this protein family
precludes effective and specific drug design, however. In
the current study we undertake such a global structure:-
function analysis. Using biochemical, structural, and
computational methods we characterize the human
cyclophilin family in detail and suggest that there is a
previously overlooked region of these enzymes that
contributes significantly to isoform diversity. We propose
that this region may represent an important target for
isoform-specific drug design.
Structure and Biochemistry of Human Cyclophilins
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Characterization of Cyclophilin Active Sites
In order to elucidate the function of residues in the extended
active site of the PPIase domain of the human cyclophilins, we
probed the binding and catalytic function of these domains against
either substrate or small-molecule inhibitors (see Figure 1 and
Datapack S1 for graphical and tabular depictions of the active
site). Three assays were utilized to explore these functions. In the
first assay, changes in thermal stability were used to assess
cyclosporin binding. This assay has been shown in several studies
to be a reliable readout of small molecule binding for kinase and
other enzyme families [37,38]. Cyclosporin A (CsA) and the
derivatives cyclosporin C, D, and H were screened against all
PPIase domains except for PPIL3 and PPIL4, for which all
constructs were insoluble or unstable in our hands (Table 1).
Because of the inherent thermal stability characteristics of PPID
and RanBP2, this technique was unable to distinguish between apo
and cyclosporin-bound forms of those domains. However, data
were collected for the remaining 13 isoforms, and binding to CsA,
CsC, or CsD was noted for six isoforms published previously
(PPIA, PPIB, PPIC, PPIE, PPIL1, and PPWD1) [20,27–30,32]. In
addition, binding of CsA or derivatives was seen for PPIF, PPIG,
PPIH, and NKTR. In the case of PPIG and PPIH, this explains
previous data describing cyclosporin binding to the tri-snRNP
complex that contains PPIH [25] and verifies the finding from a
homolog that PPIG is capable of binding cyclosporin [39]. No
binding was detected for PPIL2, PPIL6, or SDCCAG-10, making
these, to our knowledge, the first set of human cyclophilins that
have been found incompetent to ligate cyclosporin (Table 1). In
order to quantify cyclosporin affinity we undertook isothermal
calorimetry (ITC) analysis of all soluble cyclophilin isoforms; we
found that a complete family-wide screen led to a range of binding
affinities for CsA, expressed as the dissociation constant Kd, from
low nanomolar to near micromolar values. We were also able to
confirm that under the experimental conditions we tested there
was no evidence of CsA binding to PPIL2, PPIL6, or SDCCAG-
10 (Table 1).
A two-dimensional NMR experiment (1H/1H TOCSY)
described previously [30,40], the only in vitro protease-free
method available to probe for both substrate binding and catalytic
activity of cyclophilins, was used to assess the commercially
available tetrapeptides of sequence AAPF, AFPF, and AGPF [34].
The NMR-based assay confers the advantage of being a highly
sensitive assay for the detection of substrate binding in addition to
catalytic activity; the standard chymotrypsin-coupled assay can
detect only catalysis and does not provide any direct measurement
of binding [40–42]. A number of articles have documented the
drawbacks of the protease-coupled assay [33,42–44], an obvious
example being that the addition of protease to the reaction
mixture in the chymotrypsin-coupled assay requires additional
testing to ensure that the enzymes and substrates being screened
are not proteolytic targets [43]. Additionally, the NMR-based
assay does not require substrates to contain chemical modifica-
tions, and can be used to measure effects of amino acid
substitutions at regions distal to the target proline not measurable
by other methods [42]. We detected binding and turnover for at
least one of the tetrapeptide substrates tested for PPIA, PPIB,
PPIC, PPID, PPIE, PPIF, PPIG, PPIH, PPIL1, PPWD1, and
NKTR (Table 1; see Figure S1 for representative data showing
binding and activity). This correlated well with previously
determined activities [2,20,21,28,30,45,46], and established activ-
ity measurements for PPIF, PPIG, and NKTR. For all isoforms
tested there was a strict correlation between the ability to bind
cyclosporin and activity against the tetrapeptide substrates
(Table 1).
In order to understand the molecular basis of these results, we
sought structural coverage of the entire human cyclophilin
enzymatic class. We determined crystal structures of seven human
PPIase domains—PPIC, PPIE, PPIG, PPWD1, PPIL2, NKTR,
and SDCCAG-10 (Figure 2 and Datapack S1). There are six
previously determined structures (PPIA, PPIB, PPIF, PPIH,
PPIL1, and PPIL3). This leaves four structurally uncharacterized
human PPIase domains of cyclophilins (PPID, PPIL4, PPIL6, and
RanBP2) (Figure 2 and Table S1). However, if we include the
highly homologous bovine structure for PPID (three amino acid
substitutions compared to human) and compare the set of 14
isoforms for which we have experimental data, we find that they
have very similar secondary structural elements (Figure 2). We can
therefore use this dataset to provide excellent homology models for
the remaining three isoforms (PPIL4, PPIL6, and the PPIase
domain of RanBP2) (Figure 2). Models for these three isoforms
were generated using the Phyre algorithm [47], and for all further
discussions of the cyclophilin family the structures of all 17 PPIase
domains will be considered.
All cyclophilins share a common fold architecture consisting of
eight antiparallel b sheets and two a-helices that pack against the
sheets (Figures 1 and 2). In addition, there is a short a-helical turn
Figure 1. Structural elements of the cyclophilin fold and the
definition of the active surface of PPIA. (A) Secondary structural
elements of PPIA in ribbon representation, with key structural elements
labeled. All structural outputs were generated using PyMol unless
otherwise noted. (B) Consurf representation of sequence conservation
within the human cyclophilin family; residues that compose the active
surface of the cyclophilin family are labeled [81]. (C) Comparison of the
sequences that define the active surface of the PPIase domain. Residue
numbering corresponds to PPIA.
doi:10.1371/journal.pbio.1000439.g001
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region (Figure 1; all residue identities and numbers correspond to
PPIA except where noted). RMSD across all atoms for all PPIase
domains is less than 2 A ˚, and sequence identity over the same
region varies from 61% to 86% (Figures 1, S2, and S3). The most
divergent structures in this set are PPIL1, which is an NMR-
derived structure (RMSD 1.7 A ˚), and the previously described
PPWD1 (RMSD 1.4 A ˚) [30]. Excepting PPIL1 and PPWD1, the
remaining experimental PPIase domains align over all atoms with
RMSD ranging from 0.4 A ˚ to 1.0 A ˚ (see Figure 2 and also Figure
S5 for a more detailed structural alignment). An overlay of the
Phyre-derived modeled structures leads to an RMSD over all
atoms of 1 A ˚ or less compared to PPIA.
The active site of the cyclophilin family includes the invariant
catalytic arginine (Arg55) and a highly conserved mixture of
hydrophobic, aromatic, and polar residues including Phe60,
Met61, Gln63, Ala101, Phe113, Trp121, Leu122, and His126
[48–50]. All of these sidechains contribute to an extensive binding
surface along one face of the PPIase domain measuring roughly
10 A ˚ along the Arg55–His126 axis and 15 A ˚ along the Trp121–
Ala101 axis (Figure 1). Many of these residues are well conserved
across all PPIase domains and are thought to serve functions in
either catalysis or substrate/inhibitor binding [48,50,51]
(Figures 2, S2, and S3). Although there are sites of minor
diversity among the family members at the Phe60, Met61, and
His126 positions, the most striking correlation between cyclo-
sporin binding, tetrapeptide identity, and active site residues is
found at the Trp121 position. Our results clearly show that a
tryptophan (as found in PPIA, PPIB, PPIC, PPIE, PPIF, PPIH,
PPIL1, and PPWD1) or histidine (as found in PPID, PPIG,
PPIL3, RANBP2, and NKTR) at this position is permissive for
cyclosporin binding whilst other naturally occurring residues at
this position (tyrosine in PPIL2, PPIL4, and PPIL6, and glutamic
acid in SDCCAG10) abrogate cyclosporin binding under our
experimental conditions (Table 1 and Figure 3). It has been
shown that mutating Trp121 in PPIA to alanine or phenylalanine
has a negative impact on cyclosporin affinity [51–53]. Mutation
of the naturally occurring histidine in PPID to a tryptophan
increases cyclosporin affinity dramatically, altering IC50 for
cyclosporin from 1.9 mM to 28 nM and the Kd
app to 12 nM
[31,54]. There are no mutational or computational data for the
human cyclophilins that have a tyrosine or glutamic acid
substitution at the Trp121 position; we therefore made a set of
mutants to both PPIA (mutating Trp121 to either tyrosine or
glutamic acid) and to PPIL2 (mutating Tyr389 to either
tryptophan or histidine). As expected, mutation of Trp121 in
PPIA to glutamic acid abolished activity of this protein; however,
the tyrosine mutant retained the ability to catalyze proline
isomerization, a novel result. More importantly, the single
mutation of Tyr389 to tryptophan converted PPIL2 to an active
isomerase, thereby illustrating the fundamental importance of this
residue in conferring activity to the cyclophilin family (Figure
S1B). However, the Tyr389 mutation to histidine did not lead to
activity as measured by NMR under the experimental conditions
assayed. For this reason, both the Tyr389 mutants were tested for
CsA binding using ITC, and both the Tyr389Trp and Tyr389His
mutants were found to bind CsA with micromolar affinity
(1.6 mM and 6.6 mM for Trp and His respectively). Taken
together, it is clear that there is some flexibility in the active site
with regard to the Trp121 position: a tryptophan is clearly
Table 1. Cyclosporin binding and tetrapeptide activity in the human cyclophilin family.
Cyclophilin Assay Thermal Stability ITC
Tetrapeptide Activity Cyclosporin Binding Basal Tagg (uC) DTagg, CsC (uC) Kd, CsA (nM)
PPIA yes yes 45.9 1.9 6.8
PPIB yes yes 60.0 3.4 8.4*
PPIC yes yes 50.6 7.0 7.7*
PPID yes yes n/a n/a 61
PPIE yes yes 60.4 6.8 6.9
PPIF yes yes 52.4 10.7 6.7*
PPIG yes yes 55.6 2 51
PPIH yes yes 54.4 7.3 160
PPIL1 yes yes 49.1 1.7 9.8*
NKTR yes yes 45.4 3.0 488
PPWD1 yes yes 50.6 5.2 168
PPIL2 no no 50.9 n/a n/d
PPIL6 no no 60.0 n/a n/d
RANBP2 no no n/a n/a n/d
SDCCAG-10 no no 44.8 n/a n/d
PPIL3 not tested n/a n/a n/a n/a
PPIL4 not tested n/a n/a n/a n/a
Tetrapeptide activity is defined as the collapse of substrate cis/trans peaks in the presence of highly purified PPIase protein, as previously described [30,40] and shown in
Figure S1. Cyclosporin binding represents the combination of StarGazer and/or ITC data; briefly, any PPIase protein with a Tagg shift greater than 2uC in the presence of
either cyclosporin A, C, or D is shown as a positive result. n/a indicates those cyclophilins that were either not tested or do not undergo a cooperative thermal transition
[38,85]. The basal Tagg is shown for all family members for whom a cooperative thermal transition was observed, along with the observed Tagg shift for one cyclosporin
compound (CsC). ‘‘n/d’’ indicates no binding isotherm was noted in ITC under the experimental conditions outlined in this study.
*For ITC data, asterisks indicate the Ki values obtained in a recent study of isoform-selective inhibitors for six cyclophilins [67].
doi:10.1371/journal.pbio.1000439.t001
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activity, as is histidine. Glutamic acid at this position seems to be
incompatible with isomerase activity.
Previous computational work with PPIA indicates that the
function of Trp121 is mainly to serve to build a hydrophobic
pocket for the substrate proline to insert (along with Phe60, Met61,
Phe113, and Leu126) [55,56]. However, our experimental data do
not fully support this notion. To explain these results we modeled
the interaction of CsA with the active site of cyclophilins, as the
macrocyclic ring of cyclosporin structurally mimics the placement
of the substrate residues N terminal and C terminal to the target
proline (where the sequence Xaa-Pro-Yaa is denoted P1, P19, and
P29 respectively) within the active site [48,57–59]. Modeling of
either CsA into the active site of a histidine containing isoform (like
NKTR) or computational mutation of the Trp121 in a PPIA:CsA
complex structure indicated that similar hydrogen bond distances
can exist between the indole moiety of tryptophan or the imidazole
ring of histidine and the carbonyl of methylleucine 9 (MLE9) in
CsA (Figure S4). Therefore either residue would be competent for
binding, as we have shown experimentally. Conversely, a tyrosine
modeled in the conformation to coordinate with CsA created a
steric clash with the carbonyl of MLE9 (1.75 A ˚); in addition, there
was a close steric conflict with the modeled Tyr residue and Cf of
the highly conserved Phe60 residue that helps form the proline-
binding pocket (Figure S4). Perhaps this is why in our apo PPIL2
structure the tyrosine at this position pointed away from the active
surface (Figure 2). Consistent with this, electron density for Phe71
residue in NKTR indicated that alternative conformations are
possible for this residue, which may also explain why the PPIA
Trp121Tyr mutant was still capable of coordinating substrate in
vitro (Figure 2). We propose that the function of the residue at this
position is to make a specific polar interaction with either the
carbonyl of MLE9 in CsA or the carbonyl of a substrate peptide at
the P29 position (C terminal to the target proline).
Figure 3. The structural consequences of substitutions in the cyclophilin active site. The residues described in Figure 1 are shown in stick
representation for the divergent family members PPIA, NKTR, PPIL2, and SDCCAG-10. Note the orientation of the divergent residues Tyr389 in PPIL2
and Glu122 in SDCCAG-10 relative to Trp121 in PPIA or His132 in NKTR.
doi:10.1371/journal.pbio.1000439.g003
Figure 2. Structural coverage of the human cyclophilin family. Cartoon representation of the novel experimental and modeled structures of
human cyclophilins associated with this manuscript. Only the isomerase domain is shown. The previously determined structure of PPIA is shown as a
reference point, and loop regions discussed in the text are outlined with dotted ovals and labeled. The structures of RanBP2, PPIL6, and PPIL4 are
marked with an asterisk, as they are derived from homology modeling using the Phyre server [47] and do not represent experimentally derived data.
For crystallographic data concerning the structures shown here, refer to Table S1.
doi:10.1371/journal.pbio.1000439.g002
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PPIL2, PPIL6, and SDCCAG-10 (Table 1). It is clear that these
three proteins are quite divergent in the active site compared to
PPIA (Figure 1C). Perhaps more importantly they are, along with
PPIL4, the only isoforms that substitute the residue Trp121 with a
non-histidine residue. Additionally, PPIL4 does not possess the
otherwise strictly conserved Arg55 (there is an asparagine at the
equivalent position), so it is not surprising that this isoform does
not show activity against standard substrates. The molecular
function of the PPIase domain for these isoforms is unknown, but
our structures suggest that these isoforms could still serve as
proline-binding domains. Indeed, our assays show binding to the
standard substrate suc-AGPF-pNA even where we do not detect
isomerase activity (Figure S1A).
Expanding the Definition of the Cyclophilin Active Site:
The S2 Pocket and Gatekeeper Hypothesis
PPIL2, PPIL6, and SDCCAG-10 are clearly divergent from the
rest of the family in terms of in vitro activity. Next, a structural
analysis of all family members was undertaken in order to probe
for further isoform diversity. Examination of the surface of the
PPIase domains near the active site revealed two pockets that
potentially contribute to substrate specificity, binding, and
turnover. The first pocket is the proline interaction surface (or
Figure 4. The S2 ‘‘gatekeeper’’ region of the human cyclophilins. (A) The definition of the S19 pocket and S2 pocket is shown by depiction of
a complex between PPIA and the tetrapeptide suc-AGPF-pNA (PDB 1ZKF). Surface representation of charges calculated within PyMol is shown,
colored blue for basic and red for acidic regions. Residues around the active site and the S2 pocket are labeled according to PPIA numbering. (B)
Sequence diversity of the gatekeeper residues in two PPIase domain structures. An ‘‘occluded’’ cyclophilin (NKTR) is shown in comparison to PPIA. As
shown in Figure 5, these substitutions lead to diverse size and charge properties in this region of the cyclophilin active surfaces. (C) Comparison of
the amino acids that define the S2 pocket of the PPIase domain. Residue numbering corresponds to PPIA.
doi:10.1371/journal.pbio.1000439.g004
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as P19) and is defined by the PPIA residues Phe113 at the base of
the pocket and Phe60, Met61, Leu122, and His126 that form the
sides of the pocket (Figure 4). As previously described, these
residues are highly conserved across all PPIase isoforms and
orthologs, consistent with minor discrimination against commer-
cial substrates or cyclosporin [60]. The second pocket forms a
surface that likely interacts with substrate residue P2 or P3 relative
to the substrate proline, and so will be named the S2 pocket
hereafter. Since the main-chain atoms of the b5-b6 loop define the
base of the S2 pocket, the chemical identities of residues found in
this region do not have much influence on the size and shape of
the S2 pocket (Figure 4). Indeed, the S2 pocket is extremely
uniform across cyclophilins; it is deep and relatively nonspecific, so
it can accommodate long, short, polar, or hydrophobic sidechains
without penalty. However, the S2 pocket surface is guarded by a
set of ‘‘gatekeeper’’ residues whose sidechains are in a position to
control access to this pocket. In PPIA, these residues are Thr73,
Glu81, Lys82, Ala103, Thr107, Ser110, and Gln111 (Figure 4C).
These gatekeeper residues at positions 81, 82, and 103 and the
secondary gatekeeper at position 73 (so named because its position
in most PPIase structures is pointed away from the S2 pocket)
show major chemical and size variance. For instance, the residue
that is at position 103 in PPIA varies from alanine in about half of
the cyclophilin isoforms to a serine in PPIE, PPIH, and PPIL2; an
arginine in PPIG and NKTR; lysine in PPIL6; asparagine in
PPIL3 and PPIL4; and glutamine in RANBP2 (Figure 4C). The
identities of the amino acids at positions 73, 81, and 82 are equally
diverse across the cyclophilin family. The practical effect of this
variance can be visualized by examining the surface properties of
the cyclophilin family (Figure 5 and Datapack S1). These surfaces
are clearly unique to the individual cyclophilin members, but can
generally be classified into gatekeeper surfaces with mixed or
neutral charges (see for example PPIA and several others);
gatekeeper surfaces with overall acidic character (SDCCAG-10,
PPIC, and PPWD1); and gatekeeper surfaces that occlude access
to the S2 pocket (several; see Figure 5). The occluded set consists of
the cyclophilin isoforms with bulky sidechains at the gatekeeper
positions; for instance, NKTR has Lys84, Tyr93, and Arg114
compared to PPIA residues Thr73, Lys82, and Ala103 (Figures 4
and 5). Finally, residues within this region of PPIA, including
Lys82, have previously been shown to be important for substrate
binding as shown by NMR relaxation studies [61], consistent with
a gatekeeper function.
Structural Analysis of Regions Outside the Active Site
The S2 pocket is where conformational divergence throughout
the cyclophilin family is greatest (Figure 2 and Datapack S1). Most
of the remaining structural diversity is found in three of the loop
regions connecting secondary structural elements. A subset of
cyclophilins have a deletion in the b1-b2 loop region (residues
Ala11-Pro16 in PPIA) that significantly alters the b sheet lengths in
this region along with the loop between them. The division
between ‘‘deleted’’ b1-b2 loops and ‘‘full-length’’ b1-b2 loops
follows a phylogram distribution of PPIase domains, with the more
conserved isoforms relative to PPIA (PPIB, PPIC, PPID, PPIE,
PPIF, PPIG, PPIH, PPIL6, NKTR, and RanBP2) encoding full-
length loops and the more divergent members by sequence
(PPIL1, PPIL2, PPIL3, PPIL4, SDCCAG-10, and PPWD1)
encoding deleted b1-b2 loops (Figure 2 and Figure S5). The a1-
b3 loop (Thr41-Gly50) is also a region of structural diversity.
There are three distinct classes of conformations adopted by this
loop: the PPIA a1-b3 loop family, which includes PPIA, PPIB,
PPIC, PPIE, and PPIF; a shorter version of the loop represented
by the structures of PPIL1, PPIL2, PPIL3, PPIL4, SDCCAG-10,
and PPWD1; and a longer version found in PPID, PPIG, PPIH,
PPIL6, and NKTR. The short version of the a1-b3 loop changes
the orientation of the a1 helix and the b3 sheet, and causes a ,2A ˚
displacement of a1 relative to PPIA (Figure S5). Finally, the a2-b8
loop (Gly146-Lys155) has two distinct groups: the standard
conformation found in PPIA, PPIE, PPIF, PPIL6, and RANBP2,
and the conformation adopted by all other isoforms (Figure S5).
Interestingly, two regions found to have structural divergence (the
b1-b2 and a2-b8 loops) form a contiguous surface on the ‘‘back’’
face of the cyclophilin fold relative to the active site. Sequence and
structural diversity in this region could indicate a preference for
different potential binding partners, as the back face of cyclophilins
has previously been shown to mediate protein:protein interactions
[19,20]. However, it seems that for substrate interactions mediated
by the proline-binding pocket isoform selectivity is likely to be
determined by the S2 pocket region rather than these distal
regions. Thus, the functional significance of the S2 pocket will be
further explored with regard to its effect on substrate binding and
specificity.
Cyclophilin Diversity in the ‘‘S2 Gatekeeper Region’’
Our biochemical data are the latest evidence that molecular
determinants for tetrapeptide substrate or cyclosporin binding may
not be identical to molecular determinants for physiologically
relevant substrates, and supplements other recent publications
along these lines [62,63]. Additionally, structural analysis suggests
that the region surrounding the S2 pocket is an attractive target to
design isoform specificity. As commercially available ligands and
substrates are unable to effectively probe this region of the
cyclophilin family, we turned to in silico techniques to obtain
insight into isoform gatekeeper identity and its relationship to
accessibility to the S2 pocket. Four hundred test peptides of the
general form Xaa-Zaa-Gly-Pro (corresponding to substrate
positions P3-P2-P1-P19) were docked into a subset of cyclophilin
family members (PPIA, PPIL2, PPIC, PPWD1, and NKTR).
These proteins were chosen because of the diversity of the amino
acids in the gatekeeper and S2 pocket regions (Figure 5). Monte
Carlo simulations were performed to sample conformational space
for each combination of cyclophilin isoform and test peptide,
allowing flexibility of the P2 and P3 residues of the potential
substrate and of the sidechains of the gatekeepers at positions
comparable to PPIA Thr73 (gatekeeper 1), Lys82 (gatekeeper 2),
and Ala103 (gatekeeper 3) while keeping the rest of the protein
rigid [64]. The sidechain of Arg377 in PPIL2, which is a glycine in
the other cyclophilins investigated, was also allowed flexibility as it
contributes a unique chemistry to the S2 region. Throughout the
Monte Carlo simulations (200,000 iterations) tethers were imposed
on the Gly and Pro residues to ensure that the tetrapeptides would
remain bound to the active site. We made an assumption, based
on a number of previous crystallographic and NMR-based studies
of the cyclophilins, that the position and coordination of the Gly-
Pro sequence of substrate is relatively fixed within the active site of
the PPIase. Several structural studies with both synthetic and
natural substrate data bound to PPIA support this assumption
[30,50,59]. It was computationally necessary to fix the P1 and P19
positions upon the enzyme in order to allow for more degrees of
freedom at the P2 and P3 positions in our simulations; without
these tethers we would have been testing the contribution of these
two residues to the overall ability of substrate to bind the entire
active site. While this is a very interesting line of study the
interaction of proline in the proline binding or P19 pocket was not
the focus of the current work. For each combination of cyclophilin
isoform and tetrapeptide, the lowest-energy complex was chosen
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potential. The scales of the potentials are all roughly the same (average potential: 665 kBT/e) and range from 656 kBT/e for PPIG to 681kBT/e for
PPIL4; all surfaces were calculated using the protein contact potential function in PyMol. As discussed in the text, the surfaces have been generally
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estimate of the binding energy was calculated using ICM [65].
Additionally, since low-energy complexes may or may not include
significant interactions at the S2 pocket, the distance between the
tetrapeptide and the Ca of the gatekeeper equivalent to PPIA
Lys82 was calculated. This metric was designed to query for
tetrapeptides that both bind with favorable energy in the S2
pocket, and also fill the S2 pocket if possible.
An energetic preference for aromatics interacting with the S2
pocket was found for PPIA, in particular tryptophan or tyrosine
(Figure 6; for scatter plot representation see Figure S6). In
addition, there were a few peptides containing methionine, lysine,
or arginine at the P2 position that extended deeply into the S2
pocket, albeit with poor predicted binding energies. Peptides with
isoleucine, leucine, valine, proline, alanine, glycine, cysteine,
threonine, or serine at the P2 position were disfavored, with poor
predicted binding energies. We observed much less discrimination
for the identity of the P3 position, although there is a clear
selection against basic chemistries (Figure 6). Visual inspection of
the top 10 model complexes predicted for PPIA based on the
energy metric (EFGP, EWGP, DYGP, DEGP, DDGP, YWGP,
PYGP, EDGP, YFGP, and PWGP) showed that all of the residues
at the P2 position are well positioned to fill the S2 pocket of PPIA,
while inspection of some models that scored poorly (RFGP,
ERGP, DFGP) showed incomplete entry into the S2 pocket. In
addition, these models indicated interactions between the residue
at the P3 position and the gatekeeper 1 residue, or with the P19
pocket and the key active site residue Arg55.
The published data on specificity for PPIA are consistent with
our findings. Previous in vitro phage display experiments with
PPIA (designed to probe substrate preferences at the P1 to P89
positions) found a strong preference for phenylalanine at the P2
and glutamic acid at the P3 position; these residues were provided
by the expression vector used in the phage display and therefore
biased the pool of samples available for initial selection [35].
Substitution of this glutamic acid/phenylalanine series with any
other residues, however, lessened the signal on an array, thereby
confirming a preference for these chemistries in solution. Our
simulations support this chemical preference for acidic residues at
P3 followed by aromatic residues at P2 (Figure 6). A well-
characterized substrate in vivo for PPIA is the HIV capsid; there
are several sequence variants that have been studied both in
solution and in crystallographic experiments, and all sequences
have either methionine or alanine at the P2 position and histidine
or alanine at the P3 position [50,66]. In the structures of PPIA
with these peptides, the alanine does not fill the S2 pocket, and this
is likely the reason why it does not score well in our modeling
trials. Neither histidine nor alanine at the P3 position is predicted
to score highly by our modeling trials, and in the co-crystal
structures these residues are not making any significant contacts to
the gatekeeper 1 region of PPIA. The validated in vivo substrate
CD147 was also investigated. The natural sequence that is acted
upon by PPIA is ALWP, which was not predicted to bind tightly to
PPIA based on either the phage display data or our simulations,
and experimentally was found to have rather weak affinity [17].
Finally, the PPIA substrate Itk contains the targeted sequence
ENNP, which is a relatively high-scoring P3 and P2 sequence
combination based on our models [14]. Our simulations
recapitulate the experimental data that is available, but imply
that none of the in vitro or in vivo substrates studied to date for
PPIA interact with the S2 pocket with optimized space-filling or
energetic properties.
In order to begin experimental validation of our in silico
predictions, a peptide ‘‘test set’’ composed of the following
sequences was synthesized: DEGPF, DFGPF, DYGPF, YGGPF,
and VRGPF. We then monitored catalysis of all of these potential
substrates using our NMR-based assay (Figure S1). These peptides
were selected in order to allow us to discriminate between
cyclophilin isoforms; initial studies were conducted with PPIA in
order to optimize experimental conditions for the detection of
binding and catalysis. Our data indicated that, although PPIA was
competent to bind all five peptides, only those predicted to have
significant scores on the binding energy metric were substrates for
proline isomerization (DEGPF, DFGPF, and DYGPF; see Figure 6
and Figure S1). The two peptides that were not efficient substrates
for catalysis (YGGPF and VRGPF) both yielded poor predicted
binding energies in our docking study to PPIA. That there was
little discrimination with our NMR assay between DEGPF,
DFGPF, and DYGPF was somewhat inconsistent with our
simulations, as the model peptide for DFGP did not extend fully
into the S2 pocket. It is possible that while tethering the P1 and
P19 Gly-Pro sequence allowed us to obtain a large number of
reasonable structures at the P2 and P3 positions, it may have
artificially increased our in silico binding affinity in a way that we
cannot recapitulate in vitro. It is also possible that this spatial
constraint upon our simulations biased our results towards
substrates with the key interacting residue at the P2 position.
Perhaps in vitro it is the P3 position that contributes significantly to
binding energy; therefore the binding contributed by the aspartic
acid in the current test set was the significant determinant for
binding to PPIA in addition to the identity of the residue at the P2
position. Regardless, these experimental results will allow us to
next analyze the capacity of our test set to discriminate among
cyclophilin isoforms. Additionally, as all of our test peptides are
identical at the P1, P19, and P29 positions, we can see for the first
time that substitutions at amino acids in the P2 and P3 positions
have measurable effects on the ability of the broad specificity
enzyme PPIA to bind and catalyze proline containing sequences.
Distinct patterns of chemical preference were noted for PPIC,
PPIL2, NKTR, and PPWD1 (Figure 6; for scatter plot
representation see Figure S6). Much like PPIA, the PPIase
domains of PPIC and PPIL2 showed an energetic preference for
tryptophan at the P2 position; and for PPIL2 and NKTR
isoleucine, leucine, valine, proline, alanine, glycine, cysteine,
threonine, and serine at the P2 position resulted in poor predicted
binding energies and little penetration into the S2 pocket (Figure 6).
Indeed, for NKTR there were relatively few tetrapeptide
combinations with both favorable predicted binding energy and
penetration into the S2 pocket; this is easily rationalized by the
extremely narrow gap between the gatekeeper 1 and gatekeeper 3
regions in the NKTR structure, which occlude the S2 pocket and
restrict the types of residues that can stably associate with the
pocket without steric or charge clashes (Figures 5, 6). PPIC showed
a distinct preference pattern for aromatic residues at P2 preceded
by basic or aromatic residues at P3 (Figure 6). This is most likely
due to the substitution of gatekeeper 2 and the overall acidic
character of this region of PPIC relative to PPIA (Figure 5).
In the case of PPIL2, there was near equivalency between the
aromatics at position P2, with perhaps a slight energetic preference
for tryptophan but strong affinities for tyrosine and phenylalanine
divided into those with neutral or mixed charge character surrounding the S2 pocket; those with largely acidic character around the S2 pocket; and
those whose gatekeeper residue identities lead to occlusion of the S2 pocket.
doi:10.1371/journal.pbio.1000439.g005
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PLoS Biology | www.plosbiology.org 10 July 2010 | Volume 8 | Issue 7 | e1000439Figure 6. Peptide:protein simulations for five members of the cyclophilin family. At the top are detailed results for PPIA. Simulations were
set up with the structure of PPIA (PDB 1AK4) and with 400 peptides corresponding to the sequences X-Z-G-P, where X and Z are each of the possible
combinations of the naturally occurring 20 amino acids. Gatekeeper residues were allowed flexibility during the simulations and are noted for each
family member. The middle two panels are graphical representations of the PPIA results. On the left is a scatter plot with the energy metric on the y-
axis and the distance metric on the x-axis. The lower left quadrant is where the highest-scoring peptide combinations are plotted (greatest negative
energy and closest interaction with the S2 pocket). The color of each spot in the plot corresponds to the hydrogen bonding potential between that
particular peptide and PPIA, with red indicating greater values (nine for the PPIA simulation) and purple indicating lesser values (two for the PPIA
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(Figure 6). Compared to PPIL2 simulations, the results for PPWD1
were striking: the acidic surface characteristics of this isoform
selected strongly for an arginine at the P2 position, while lysine
and aromatic residues also yielded good predicted binding energies
(Figures 5 and 6). Of the surfaces tested, only PPWD1 provided a
surface where strong energy scores were measured for basic
residues at this position. Experimentally, the construct used
initially for crystallization of PPWD1 contained a sequence AEGP
found N-terminal to the PPIase domain, and this sequence was
found associated with a neighboring PPIase domain in the crystal
structure. NMR-based assays showed that AEGP bound PPWD1
but was not a good substrate for the enzyme, which correlates well
with the poor binding energy predicted for the AEGP tetrapeptide
in our simulations [30]. Again, the scarcity of experimental data
for cyclophilin isoforms limits the ability to validate the
simulations; but to the extent that such information exists, it
correlates well with our in silico findings. Current efforts are
underway to measure binding and/or proline isomerization of our
test set peptides with NKTR, PPIC, PPIL2, and PPWD1; we
predict based on our above analysis that several of our test set
peptides would bind well to most or all of our test cyclophilins (see
DYGP and DFGP in Figure 6), while others could be selective for
some isoforms over others (VRGP, which has good energy metrics
for PPWD1 but not for any other isoform in the current study).
Although in vitro validation of our in silico results are still ongoing,
we believe that the initial data we present here provide the basis
for a renewed study of the S2 pocket of the human cyclophilins as
a potential locus of chemical and substrate diversity.
In conclusion, there are cyclophilin family members that, while
sharing overall conservation with active members of the family, do
not possess isomerase activity in our assays. For PPIL2 and
SDCCAG-10, both of which have been found associated with
spliceosomal complexes, it may be that it is the non-active surface
of the PPIase domain that performs the major function as in the
cases of PPIH and PPIL1. Additionally, it may well be that the
function of the PPIase domain in these cyclophilins is to simply
bind proline-containing motifs. Our NMR data suggest this
option, as binding without measurable catalysis to proline
sequences is observed for all isoforms we were able to test.
Chemical probes such as cyclosporin are unselective with regard
to the cyclophilin family (Table 1) [67]. Although a recent report
focusing on aryl 1-indanylketones showed binding to PPIA, PPIF,
and PPIL1 while not binding to PPIB, PPIC, or PPIH [67], it seems
that anyligand that coordinates exclusively with the S19 pocket and/
or Trp121 region is unlikely to be selective with respect to the entire
cyclophilin family. Potentially, the S29 or S39 region of the isomerase
domain could be a site of selectivity; it is clear from our surface
representations (Figure 5) thatthis isa variable partof thecyclophilin
domain. However, our results indicate that a clear virtual chemical
fingerprint exists for the S2 and S3 positions of the isomerase
domain.Forinstance,PPIAandPPWD1 seem tohave restricted sets
of sidechains that are preferred at the P2 position (and the P3
position in the case of PPIA), while PPIC appears to be more
promiscuous. The highly occluded nature for the S2 pocket
exhibited by NKTR results ina restrictive set of allowed tetrapeptide
sequences for this isoform; several other isoforms in the cyclophilin
family also exhibit this type of gatekeeper restriction. Because of the
very distinct molecular features of the S2 region, both in terms of the
highly ‘‘druggable’’ S2 pocket and the chemical diversity seen for the
gatekeeper residues, targeting this region of the cyclophilins for
pharmacophore design and selection is more likely to result in tight
binders with greater specificity for particular isoforms in the family.
Materials and Methods
Cloning, Expression, and Purification of Isomerase
Domains
Detailed materials and methods for cloning, expression,
purification, and crystallization of all novel isomerase domain
structures solved as part of the Structural Genomics Consortium
are freely available at the Web site http://www.sgc.utoronto.ca/;
where methods differ significantly from the following they are
noted for each isoform in Text S2. In general, full-length cDNA
clones were obtained from the Mammalian Gene Collection
(accession numbers noted below). Constructs based around the
predicted isomerase domain boundaries were cloned into pET28a
using ligation-independent cloning methods (LIC) (BD Bioscienc-
es, San Jose, CA, USA) and transformed into BL21 Gold DE3 cells
(Stratagene, La Jolla, CA, USA). The resulting vectors encode an
N-terminal His6 tag with a thrombin cleavage site. Mutants of
cyclophilin constructs were created either using standard Quick-
change protocols (Stratagene) or by LIC-based methods on PCR
fused gene products. Cultures were grown in Terrific Broth
medium at 37uCt oO D 600 of 6 and induced at 15uC overnight
with the addition of 50–100 mm isopropyl thio-b-D-galactoside
(IPTG). Pellets were resuspended in 20 mL of lysis buffer (50 mm
Tris, pH 8.0, 500 mm NaCl, 1 mm phenylmethanesulfonyl
fluoride and 0.1 mL of general protease inhibitor (P2714, Sigma,
St. Louis, MO, USA) and lysed by sonication; lysates were then
centrifuged for 20 min at 69,673g. The supernatant was loaded
onto nickel nitrilotriacetic acid resin (Qiagen, Valencia, CA, USA),
washed with five column volumes of lysis buffer and five column
volumes of low imidazole buffer (lysis buffer+10 mm imidazole,
pH 8), and eluted in 10 mL of elution buffer (lysis buffer+250 mm
imidazole, pH 8, and 10% glycerol). If the His6 tag was cleaved for
crystallization purposes, then one unit of thrombin (Sigma) per
milligram of protein was added to remove the tag overnight at
4uC. For gel filtration, a column packed with HiLoad Superdex
200 resin (GE Healthcare, Piscataway, NJ, USA) was pre-
equilibrated with gel filtration buffer (lysis buffer+5m M b-
mercaptoethanol and 1 mM ethylenediaminetetraacetic acid).
Peak fractions were pooled and concentrated using Amicon
concentrators (10,000 molecular mass cut-off; Millipore, Danvers,
MA, USA). The protein was generally used at 250–500 mM for
crystallization screening.
Crystallization and Structure Solution of Isomerase
Domains
Generally, crystal hits were initially prepared in sitting drop 96-
well format. Proteins were set up as 1 mL protein+1 mL reservoir
simulation). Scatter plots for all other simulations are found in Figure S6. In the panel on the right, the identity of the residue at position P3 is plotted
along the x-axis, and the identity of the residue at the P2 position is plotted along the y-axis. The general chemical classification for each residue set is
indicated. At the intersection of each x, y point is a square representing the binding energy and distance metrics. Red indicates greater binding
energy for that x, y pair; purple indicates lesser energy. Value ranges for PPIA were 25.5 (red) to 4.3 (purple). Larger squares fill the S2 pocket to a
greater extent. The bottom four panels are x, y arrays for four other cyclophilin simulations. Coloring and axes are as in the middle right panel. Note
that the energy value ranges for the five x, y arrays are not identical and are as follows: NKTR (red=27.0, purple=5.0), PPIC (red=25.9, purple=1.3),
PPIL2 (red=24.7, purple=1.9), PPWD1 (red=27.0, purple=1.0).
doi:10.1371/journal.pbio.1000439.g006
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optimization was required it was performed in 24-well hanging
drop format with 1 mL protein+1 mL reservoir solution. Crystals
were cryoprotected with mother liquor with 10%–15% glycerol.
Datasets were collected on an in-house FR-E SuperBright Cu
rotating anode/Raxis IV++ detector (Rigaku Americas, The
Woodlands, TX, USA); except for PPIC, which was collected at
APS 19-BM. Data was integrated and scaled using the HKL2000
program package [68,69]. The program PHASER [70] was used
as part of the CCP4 suite [71] to find the molecular replacement
solution. Manual rebuilding was performed using either O [72] or
COOT [73], and refined using REFMAC [74] in the CCP4I
program suite [75]. In most cases ARP/wARP was utilized to
assist in model building and iterative refinement of starting phases
[76]. Final models were evaluated using PROCHECK [77] and
MOLPROBITY [78], with all models judged to have excellent
stereochemistry and no residues in disallowed regions of
Ramachandran space.
PPIC. Specifically, optimized PPIC crystals were obtained
using the hanging drop vapor diffusion method. Crystals grew
when the protein (encoding residues at 15 mg/mL was
preincubated with cyclosporin A in a 1:2 molar ratio for at least
overnight and then mixed with the reservoir solution in a 1:1
volume ratio. The drop was equilibrated against a reservoir
solution containing 25% PEG MME 550, 0.1 M zinc acetate,
0.1 M MES at pH 6.5.
PPIE. Diffracting crystals leading to the structure grew when
the protein was mixed at 20 mg/mL with the reservoir solution
(containing 34% PEG 8K, 0.2 M NH4SO4, and 0.1 M bis-Tris,
pH 6) in a 1:1 volume ratio.
PPIG. Purified PPIG K125A/E126A (indicating mutations at
the indicated residues) was crystallized using the sitting drop vapor
diffusion method at 18uC by mixing 0.2 ml of the protein solution
with 0.2 ml of the reservoir solution containing 2 M NH4SO4,
0.2 M NaCl, 0.1 M Hepes, pH 7.5.
PPIL2. Diffracting crystals leading to the structure grew when
the protein was mixed at 20 mg/mL with the reservoir solution
(containing 0.8 M KNa-tartrate, 0.1 M Hepes, pH 7.5) in a 1:1
volume ratio.
PPWD1. Purified PPWD1 was crystallized using the hanging
drop vapor diffusion method. Crystals grew when the protein
(12 mg/mL) was mixed with the reservoir solution in a 1:1 volume
ratio, and the drop was equilibrated against a reservoir solution
containing 1.7 M NH4SO4, 0.1 M Na-cacodylate, 0.2 M Na-
acetate, pH 5.7. Full methods can be found in [30].
NKTR. Crystals grew in hanging drop format when protein at
15 mg/mL was mixed with reservoir containing 21% PEG 3350,
0.25 M KSO4 in a 1:1 ratio.
SDCCAG-10. Crystals were obtained when the protein at
20 mg/mL was mixed with reservoir solution containing 20%
PEG 3350 and 0.2 M NaI in 1:1 ratio in hanging drop format.
Thermal Stabilization Assay
All protein samples used for static light scattering (StarGazer)
trials were assessed for purity utilizing SDS-PAGE and verified for
mass accuracy using mass spectrometry. Methods were generally
as described as in [38]; protein at approximately 20 mM
concentration was heated from room temperature to 80uCi n
the presence or absence of small molecules, including cyclosporins
A, C, D, or H (LKT Labs, MN, USA). The cyclophilins were
originally prepared in 100% DMSO at 50–100 mM concentra-
tion, then diluted to 50 mM for screening, thereby ensuring the
final DMSO concentration was less than 5% during the
experiment. Ligand binding was detected by monitoring the
increase in Tagg in the presence of the ligand; and any compound
that caused a .2uC increase in Tagg were observed to be outside of
the range of experimental error. Each compound was tested at
least twice.
Isothermal Calorimetry
All experiments were performed using a VP-ITC microcalo-
rimeter (Microcal, MA, USA), and data analysis was performed
utilizing the Origin 7 software. All experiments were conducted at
25uC. Methods were roughly based on those in [67], with
modifications as described. Highly pure proteins were dialyzed
into ITC buffer (50 mM Hepes pH 8, 0.2 M NaCl), which was
also used to dilute ligand stock to the concentrations used for ITC.
In order to obtain strong signal for binding isotherms, proteins
were used at concentrations ranging from 50 to 300 mM, with
100 mM being standard for most cyclophilins tested. The proteins
were loaded into the syringe, with the ligand (cyclosporin A, LKT
Labs, MN, USA) in the cell at 5 mM concentration. Generally 5–
10 mL injections of protein were made; optimal volumes were
determined experimentally to obtain reasonable data for single-site
fitting. Ligands were described as not binding protein under these
conditions if, at high concentrations of protein (,300 mM), no
change in isotherm deflection was noted after 10–20 injections
(275 mL of protein).
NMR-Based Activity Assay
Most protein samples aimed at assessing binding and/or
catalysis of tetrapeptide substrates were diluted to 500 mL with
10% D2O and placed into a Shigemi microcell (Allison Park, PA,
USA). Typical samples contained 0.075 mM protein and 2 mM of
suc-AAPF-pNA, suc-AFPF-pNA, or suc-AGPF-pNA (Bachem),
along with 100 mM phosphate buffer pH 7 and 100 mM NaCl.
Spectra were collected at 25uC on a Varian 600 or 900 MHz
spectrometer (Palo Alto, CA, USA). Spectra were acquired using
standard Varian BioPack sequences, processed using NMRpipe
software [79] and visualized using CCPN software [80]. For
samples used to assess binding of PPIA to peptides DEGPF,
DFGPF, DYGPF, YGGPF, or VRGPF, samples were as above
except protein concentration was 0.3 mM and spectra were
collected at 10uC.
Monte Carlo Simulations
A set of 400 test peptides of the general form X-Z-Gly-Pro were
docked to a subset of cyclophilin isoforms (Protein Data Bank
[PDB] codes: PPIA, 1AK4: PPIL2, 1ZKC; PPIC, 2ESL; PPWD1,
2A2N; and NKTR, 2HE9) using ICM software (Molsoft LLC).
Monte Carlo simulations were performed to sample conforma-
tional space for each combination of cyclophilin isoform and test
peptide, allowing flexibility of the tetrapeptide and the sidechains
of the gatekeepers at positions comparable to PPIA Thr73, Lys82,
and Ala103, and keeping the rest of the protein receptor rigid [64].
The crystal structure of PPWD1 (PDB: 2A2N) was used to
determine the initial position of each tetrapeptide in the various
cyclophilin isoforms by superimposing the Gly and Pro residues
onto the corresponding residues bound to the active site of
PPWD1, and the catalytic arginine was repositioned to align with
Arg535 of PPWD1. Throughout the Monte Carlo simulations
(200,000 iterations), tethers were imposed on the C-terminal Gly
and Pro residues, to ensure that the tetrapeptides would remain
bound to the active site. For each combination of cyclophilin
isoform and tetrapeptide, the lowest-energy complex was chosen
as the predicted conformation of the bound complex, and an
estimate of the binding energy was calculated using ICM (Molsoft,
LLC) [65]. Additionally, the distance between the tetrapeptide and
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(this residue is located at the far end of the S2 pocket; see Figure 4),
to determine how well the docked peptide was predicted to fill the
S2 pocket. Peptides derived from simulation data were synthesized
without modification by the Core Facility at Tufts University
(http://tucf.org/).
Accession Numbers
PDB codes for the novel cyclophilin structures presented within
this manuscript are as follows: 2R99 (PPIE), 2ESL (PPIC), 2HE9
(NKTR), 2GW2 (PPIG), 2HQ6 (SDCCAG-10), 1ZKC (PPIL2),
and 2A2N (PPWD1). PDB codes for the previously deposited set of
structures used to generate figures and analyzed in the text are:
2CPL (PPIA), 2BIT (PPIF), 1CYN (PPIB), 1QOI (PPIH), 1XWN
(PPIL1), and 2OK3 (PPIL3). GenBank accession numbers for
the cyclophilins noted in the methods are: BC003026 (PPIA),
BC020800 (PPIB), BC002678 (PPIC), BC030707 (PPID),
BC008451 (PPIE), BC005020 (PPIF), BC001555 (PPIG),
BC003412 (PPIH), BC003048 (PPIL1), BC000022 (PPIL2),
BC007693 (PPIL3), BC020986 (PPIL4), BC038716 (PPIL6),
NM006267 (RANBP2 - synthetic template), BC015385 (PPWD1),
BC167775 (NKTR), and BC012117 (SDCCAG-10).
Supporting Information
Datapack S1 Standalone iSee datapack - contains the
enhanced version of this article for use offline. This file
can be opened using free software available for download at
http://www.molsoft.com/icm_browser.html.
Found at: doi:10.1371/journal.pbio.1000439.s001 (ICB)
Figure S1 Characterization of isomerases using an
NMR-based tetrapeptide activity assay. Amide-beta corre-
lations of the Ala within the suc-AGPF-pNA peptide are shown
from the 1H-1H TOCSY experimental results. Resonances in black
are from peptide in the absence of protein; resonances in red are
observed upon addition of the isomerase noted above each panel. If
there is acceleration of cis–trans isomerization that occurs on the fast
NMR time scale—i.e., faster than the chemical shift differences
between cis and trans resonances—then the individual resonances
coalesce into a singlesetofresonances. (A)Wild-type enzymes tested
in the presence of commercial substrate suc-AGPF-pNA. PPID and
PPIG are two examples of active isomerases, while PPIL2 and
SDCCAG-10 are not active under the experimental conditions
tested. Notice in the cases of PPIL2, and especially SDCCAG-10,
that although the resonances do not coalesce—and therefore there
is no significantenhancement ofisomerization—the peak centersdo
shift, indicating that the chemical environment of the peptide is
changing upon addition of enzyme. This is defined as binding, but
not catalysis, for this protein:substrate pair. (B) Effects of mutations
upon PPIA and PPIL2. Mutation of PPIA Trp121 to tyrosine
knocksout enzymaticactivityuponsuc-AGPF-pNA,whilemutation
of PPIL2 Tyr289 to histidine confers activity to this previously
inactive isomerase. (C) Activity of PPIA against peptides derived
from computational data.
Found at: doi:10.1371/journal.pbio.1000439.s002 (7.11 MB TIF)
Figure S2 Sequence alignment of the human cyclophilin
isomerase domains. Key structural and catalytic residues
discussed in the text are labeled. Alignment was generated using
ClustalX [82,83].
Found at: doi:10.1371/journal.pbio.1000439.s003 (9.89 MB TIF)
Figure S3 Sequence-based data for the human cyclo-
philin isomerase domains. (A) Phylogenetic tree with domain
organization for the 17 annotated members of the cyclophilin
family of isomerases. (B) A graphical representation of the motifs
found in multidomain cyclophilins. Both figures were generated
using the Interactive Tree of Life server [84]. (C) Diagonal table
showing the percent sequence similarity between the isomerase
domains.
Found at: doi:10.1371/journal.pbio.1000439.s004 (1.05 MB TIF)
Figure S4 The modeled effects of the residue identity at
position 121 in relation to cyclosporin A binding. In (A),
the experimental structure of a complex between PPIA and
cyclosporin A (PDB 2RMA) is shown. The distance between the
carbonyl moiety of methylleucine 9 and the indole nitrogen of
Trp121 is shown. In (B), Trp121 is shown mutated to histidine.
The sidechain is oriented with a preferred rotamer conformation
and corresponds to the experimentally observed rotamer found in
NKTR, which has a naturally occurring histidine at this position.
In (C), Trp121 is shown mutated to a tyrosine. The sidechain is
oriented with a preferred rotamer position; the steric clashes with
Cf of Phe60 and the carbonyl group methylleucine 9 are
highlighted in this orientation. In PPIL2, which naturally encodes
a tyrosine at this position, the rotamer found is oriented such that
it avoids these potential steric clashes (see Figure 2).
Found at: doi:10.1371/journal.pbio.1000439.s005 (2.63 MB TIF)
Figure S5 Regions of structural diversity in the human
cyclophilins. (A) An overlay of PPIA in blue, PPWD1 in red,
PPID in grey, and NKTR in pink are shown. Alignment is
global over all atoms, and for all structures is less than 2 A ˚ (1.4
A ˚ for PPWD1, 0.491 A ˚ for PPID, and 0.631 A ˚ for NKTR).
Regions of structural diversity are highlighted with labels and
zoomed in the panels below. (B) The structure of the b1-b2l o o p
region is shown for PPIA and PPWD1. (C) The structure of the
a1-b3 loop region is shown for PPIA, PPWD1, and NKTR. (D)
The structure of the a2-b8 loop is shown for PPIA, PPID, and
NKTR.
Found at: doi:10.1371/journal.pbio.1000439.s006 (3.62 MB TIF)
Figure S6 Additional results from simulations. Scatter
plots corresponding to the dynamic simulations on NKTR, PPIC,
PPIL2, and PPWD1 are shown. Axes and coloring are as in
Figure 6.
Found at: doi:10.1371/journal.pbio.1000439.s007 (2.23 MB TIF)
Table S1 Crystallographic data and refinement statis-
tics.
aHighest-resolution shell is shown in parentheses.
bRsym=100 6sum(| I2, I .|)/sum(, I .), where I is the observed
intensity and , I . is the average intensity from multiple observa-
tions of symmetry-related reflections.
cRfree value was calculated with
5% of the data.
Found at: doi:10.1371/journal.pbio.1000439.s008 (1.81 MB TIF)
Text S1 Instructions for installation and use of the
required Web plugin (to access the online enhanced
version of this article).
Found at: doi:10.1371/journal.pbio.1000439.s009 (0.75 MB PDF)
Text S2 Supplemental methods.
Found at: doi:10.1371/journal.pbio.1000439.s010 (0.03 MB
DOC)
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